Paper Details

  1. Home
  2. Paper Details

The odyssey of pacritinib in myelofibrosis.

Author: MascarenhasJohn, VenugopalSangeetha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pacritinib (PAC), a selective multikinase inhibitor, was developed for patients with myelofibrosis (MF) and thrombocytopenia. Two phase 3 trials (PERSIST-1 and PERSIST-2) demonstrated PAC's efficacy in reducing splenomegaly and improving symptoms in patients with platelets ≤ 50 × 109/L. The initial clinical hold on PAC due to potential bleeding and cardiac events was lifted after further review, leading to its approval for MF patients with severe thrombocytopenia.
Paper Details　
Original Abstract of the Article :
Myelofibrosis (MF) can present with symptomatic splenomegaly and/or cytopenias including thrombocytopenia. Disease-related thrombocytopenia is a poor prognostic factor with a median overall survival of less than 2 years. Currently approved JAK1/2 inhibitors have not been evaluated in patients with p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631669/

データ提供：米国国立医学図書館（NLM）

Pacritinib: A New Oasis in the Desert of Myelofibrosis

Myelofibrosis (MF), a debilitating bone marrow disorder, can lead to a range of debilitating symptoms, including splenomegaly and thrombocytopenia. This research, like a camel caravan seeking a safe haven in the desert, explores the potential of pacritinib, a selective JAK2 inhibitor, for treating patients with MF and thrombocytopenia. The authors discuss the development of pacritinib, its efficacy in clinical trials, and its potential to address the unmet needs of patients with this challenging condition.

Pacritinib: A Promising Treatment for Myelofibrosis with Thrombocytopenia

The authors discuss the results of two phase 3 clinical trials (PERSIST-1 and PERSIST-2) that evaluated the efficacy and safety of pacritinib in patients with MF. While PERSIST-1 met its primary endpoint, the development of pacritinib faced a temporary setback due to concerns about bleeding and cardiac events. However, subsequent review of the data did not confirm an excess of these events, and pacritinib was ultimately approved for the treatment of patients with MF and platelets ≤ 50 × 109/L.

Navigating the Desert of Myelofibrosis: A New Path to Hope

This research offers a beacon of hope for patients with MF and thrombocytopenia. Pacritinib, a novel therapeutic agent, has been approved for the treatment of this challenging condition, potentially improving outcomes and quality of life for patients.

Dr.Camel's Conclusion

This research underscores the importance of continued research and development in the fight against MF. Pacritinib, a promising new treatment option, represents a significant step forward in addressing the unmet needs of patients with this complex disease. Further research is needed to optimize the use of pacritinib and to develop even more effective therapies for MF.

Date :
  1. Date Completed 2022-08-25
  2. Date Revised 2023-09-18
Further Info :

Pubmed ID

35622972

DOI: Digital Object Identifier

PMC9631669

Related Literature

Article Analysis
・Effects of pacritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.